Raltegravir with optimized background therapy for resistant HIV-1 infection - Wikidata - awgldk - TriplyDB

Raltegravir with optimized background therapy for resistant HIV-1 infection

Raltegravir with optimized background therapy for resistant HIV-1 infection

http://www.wikidata.org/entity/Q28288290

about

Peptides that bind the HIV-1 integrase and modulate its enzymatic activity--kinetic studies and mode of action Virological and cellular roles of the transcriptional coactivator LEDGF/p75 A report of lung adenocarcinoma with HIV carrier and the literature review P2' Benzene Carboxylic Acid Moiety Is Associated with Decrease in Cellular Uptake: Evaluation of Novel Nonpeptidic HIV-1 Protease Inhibitors Containing P2 bis-Tetrahydrofuran Moiety A new class of multimerization selective inhibitors of HIV-1 integrase Long-term efficacy and safety of raltegravir in the management of HIV infection.Approved Antiviral Drugs over the Past 50 Years Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials Drug-class specific impact of antivirals on the reproductive capacity of HIV The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial Raltegravir cerebrospinal fluid concentrations in HIV-1 infection Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009 Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97A Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy.Assessing overall evidence from noninferiority trials with shared historical data.Noninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral Therapy A note on partial covariate-adjustment and design considerations in noninferiority trials when patient-level data are not available.HIV integrase inhibitors: a new era in the treatment of HIV.Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers.A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies.Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro.Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort Similar efficacy and tolerability of raltegravir-based antiretroviral therapy in HIV-infected patients, irrespective of age group, burden of comorbidities and concomitant medication: Real-life analysis of the German 'WIP' cohort.Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy.Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or C Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy Raltegravir: The evidence of its therapeutic value in HIV-1 infection.Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.

P2860

Q24316120-6547CA44-B1D8-42E0-B236-7744C458FA2E Q24634176-8D97661C-42DB-4E9B-A557-B9F3E603A2EC Q26820860-5A50F761-277F-4115-8300-132853078906 Q27679177-ABF36A56-A49A-448F-B502-B8A7DD736C4E Q27683994-F403BDDC-A8AF-447B-AB1D-7321C7A046BC Q27686870-41A756E8-A672-4FCA-93A9-AE97252C75A9 Q27755387-23E3F5B5-6933-45AC-921F-959B8033B805 Q28077053-FD76EC7A-87E2-4A28-8F23-003820376DA4 Q28473451-3B40A4CE-AF5E-4A53-9A9A-0C41A10D2BEC Q28475076-B92FF649-89C7-406C-BB68-873923A78007 Q28476050-1E7B2A46-DAC0-4A10-B2DD-6A086E651269 Q28476489-739D72EE-FB96-4439-BD58-EE961FF9291F Q28478722-CB735F8F-4C67-4EDB-B9D9-C763DE1832CE Q28484930-EAACE042-805D-40E9-AFF6-9AA43807B715 Q28536951-7130EF6A-37BC-4C80-960C-025B610AF439 Q28731610-DE76B862-BF5F-4C0B-A34C-5AF576E35EA7 Q30494064-D42C7824-2CE5-495B-BC26-57FD155416B0 Q30567163-52743C64-208C-454D-8804-110F7D45F3D7 Q30609066-2FECB09E-E9BA-482A-B0BB-33D0FAF87FE1 Q30662286-429E61C0-AE8F-4E96-A364-EAD6E79A20A7 Q30956943-D346E696-E094-4BEA-857D-C7014B98B20C Q33559015-D68D4762-3228-4915-84E2-47208D669CDB Q33559216-77C1D411-7648-4B52-BE4B-9BFBF2B34A18 Q33570427-E3B444EE-2358-4530-A7D3-3C31B1E0D92D Q33613775-EDC37ED7-955E-432A-9CA2-D6A51DD9D88A Q33629439-E64FF891-05B7-4AA2-8FDF-8A020F4BE601 Q33853922-55DD9B96-3576-4026-8FEA-6686315C9180 Q33880221-D470E7EA-57AA-42BD-8D21-6E9C0EADCB2D Q33887352-F997CB05-7270-4ACF-9050-CB28129260A0 Q33888718-08549029-49B4-49F1-879A-0C01C67E7236 Q33888845-BFECB4AF-DD95-42D8-B90A-D2AC58763B91 Q33910771-B8F16F02-973C-46D1-9E88-AC2005021AA9 Q33910849-D2D5CC7A-88D3-4A3A-8607-17614130AABA Q33931265-841247B7-5233-431B-8C48-F2E02920F951 Q33935930-1338CA63-67D7-4EFB-B0E7-99B77E62E722 Q33940800-6B6875CE-6B86-48F8-B488-0B072A3E0B42 Q33945171-55D92903-F69D-4CC7-B7D9-CB3D3131A753 Q33962223-44CE2517-A896-481E-84A3-89E6F609DCD8 Q33973930-076DF7FA-D1A8-4785-95FA-A4AC2BD72640 Q34035275-CCBDDFFE-E77A-4D74-95F6-D913F701DE89

P2860

Raltegravir with optimized background therapy for resistant HIV-1 infection

http://www.wikidata.org/entity/Q28288290

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Raltegravir with optimized background therapy for resistant HIV-1 infection

@ast

Raltegravir with optimized background therapy for resistant HIV-1 infection

@en

Raltegravir with optimized background therapy for resistant HIV-1 infection

@nl

type

label

Raltegravir with optimized background therapy for resistant HIV-1 infection

@ast

Raltegravir with optimized background therapy for resistant HIV-1 infection

@en

Raltegravir with optimized background therapy for resistant HIV-1 infection

@nl

prefLabel

Raltegravir with optimized background therapy for resistant HIV-1 infection

@ast

Raltegravir with optimized background therapy for resistant HIV-1 infection

@en

Raltegravir with optimized background therapy for resistant HIV-1 infection

@nl

P1433

Q28288290-481B7CB7-FD43-4989-B828-A2F5C712FFEC

P1476

Q28288290-27C15B80-87A1-4549-A2BC-BC3EEDC2B3DC

P2093

Q28288290-00078056-3E7B-42C1-BA5D-7ED0D703BB9A

Q28288290-081B9544-1C7C-45FC-B110-4C74336320CE

Q28288290-15C872ED-2286-48CA-B336-E1E89A69B9B4

Q28288290-2CB70A81-B1BC-451C-B6AB-3EADD329FCE4

Q28288290-3C28158E-DF0A-4F31-B563-CBB905811571

Q28288290-414E96BF-C250-41F6-8658-C8BE9AD7D0A4

Q28288290-46C10F43-6BE1-4608-AD66-A64E6FFA6463

Q28288290-46C5BC00-8208-4EDD-A96B-C7AF5AB52805

Q28288290-48A34737-13EC-4356-8C77-6BE2D2524478

Q28288290-4DAC3FF3-A469-4DCA-A182-407BDE907739

P304

Q28288290-C38D3018-3285-41E6-9D10-1AB36D2BD1F8

P31

Q28288290-610D60FF-EB61-4D0B-9BE3-3C3A791BEB20

P3181

Q28288290-D9E66A02-44F1-45B2-BBD4-C50DC200A31D

P356

Q28288290-5D0F740D-8C37-43A7-95B4-CD39CFB8C4FC

P407

Q28288290-F3EC510D-7456-4A11-B1C5-B62020FA3829

P433

Q28288290-053EE87E-7213-4A0D-A082-A4DA23B6CFF3

P478

Q28288290-0F8F07A2-DA40-46EA-9AC0-DA2E720050B5

P50

Q28288290-42BCFF97-8193-466E-85B3-A720B34A1F48

Q28288290-B99C5E2F-70B1-44E6-855C-905A1967B94F

Q28288290-CECE78A8-8A1D-44ED-BEAE-3B881EE688F3

Q28288290-DCC38053-0D83-4E8C-9FC9-882C416E1E2B

Q28288290-DE56345D-18AD-4358-BD77-534F77DD2690

P577

Q28288290-5E7E99FB-9C5F-4FBE-AA11-5E6AD416E8E2

P698

Q28288290-52E73B95-EF50-477C-92DC-C63217E4E2E9

P3181

P356

P1433

The New England Journal of Medicine

P1476

Raltegravir with optimized background therapy for resistant HIV-1 infection

@en

P2093

Anne R Meibohm

http://www.w3.org/2001/XMLSchema#string

Bach-Yen Nguyen

http://www.w3.org/2001/XMLSchema#string

Daria J Hazuda

http://www.w3.org/2001/XMLSchema#string

David A Cooper

http://www.w3.org/2001/XMLSchema#string

Desmond M Ryan

http://www.w3.org/2001/XMLSchema#string

Hedy Teppler

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Lennox

http://www.w3.org/2001/XMLSchema#string

Jing Zhao

http://www.w3.org/2001/XMLSchema#string

John A Killar

http://www.w3.org/2001/XMLSchema#string

Jose M Gatell

http://www.w3.org/2001/XMLSchema#string

P304

339-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1908142

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA0708975

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

359

http://www.w3.org/2001/XMLSchema#string

P50

Bonaventura Clotet Sala

Mauro Schechter

Jürgen Rockstroh

Christine Katlama

Adriano Lazzarin

P577

2008-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18650512

http://www.w3.org/2001/XMLSchema#string